twolf
Junior Member
Posts: 16
|
Post by twolf on Aug 24, 2014 18:33:47 GMT -8
Apparently extended ADT may lead to lowering your bone mineral density. It has always been my assumption that this is dues to the extremely low testosterone level while on ADT rather than the ADT agent. A urologist is trying to tell me that Degarelix (Firmagon) does not lower your BMD as severely as Lupron does. I can't find any reference to confirm or dispute this. Comments?
|
|
|
Post by Tony Crispino on Aug 25, 2014 8:02:06 GMT -8
I can honestly state that the urologist misspoke. [Original poster stated Eligard. This reply if for Eligard]
Eligard is Leuprolide Acetate. So is Lupron. Nothing else added. Both lower testosterone. It is that drop in testosterone that is associated with development of osteoporosis.
I don't really know much else to say? LHRH agonists and GnRH antagonists all lower T levels. They all carry the same side effects of that.
|
|
|
Post by Allen on Aug 25, 2014 16:05:44 GMT -8
He meant degarelix (which is Firmagon). According to the attached meta-analysis, degarelix had a lower risk of joint symptoms and fractures, as well as urinary symptoms and cardiovascular events. Degarelix better than agonists.pdf (129.33 KB)
|
|
twolf
Junior Member
Posts: 16
|
Post by twolf on Aug 26, 2014 7:07:12 GMT -8
Yes, I did mean Degarelix, corrected above; thanks Allen.
|
|